

## Research Article

\*Present address: Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, and Department of Bioengineering, University of Pennsylvania, Philadelphia, 19104, PA, USA.

**Cite this article:** Pedron CN, Freire KA, Torres MDT, Lima DB, Monteiro ML, Menezes RRPPB, Martins AMC, Oliveira Junior VX (2020). Arg-substituted VmCT1 analogs reveals promising candidate for the development of new antichagasic agent. *Parasitology* **147**, 1810–1818. <https://doi.org/10.1017/S0031182020001882>

Received: 17 June 2020

Revised: 10 August 2020

Accepted: 3 September 2020

First published online: 2 October 2020



**Key words:**

Antimicrobial peptides; Chagas disease; scorpion venom peptide; *Trypanosoma cruzi*; VmCT1

**Author for correspondence:**

Vani Xavier de Oliveira Junior,  
E-mail: [vani.junior@ufabc.edu.br](mailto:vani.junior@ufabc.edu.br)

# Arg-substituted VmCT1 analogs reveals promising candidate for the development of new antichagasic agent

Cibele Nicolaski Pedron<sup>1,3</sup>, Katielle Albuquerque Freire<sup>1</sup>,  
Marcelo Der Torossian Torres<sup>1,\*</sup>, Dânya Bandeira Lima<sup>2</sup>, Marília Lopes Monteiro<sup>2</sup>,  
Ramon Róseo Paula Pessoa Bezerra de Menezes<sup>2</sup>, Alice Maria Costa Martins<sup>2</sup>   
and Vani Xavier Oliveira Junior<sup>1,3</sup> 

<sup>1</sup>Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, 09210580, SP, Brazil;

<sup>2</sup>Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Ceará, Fortaleza, 60430372, CE, Brazil and <sup>3</sup>Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, 04044020, SP, Brazil

**Abstract**

VmCT1 is an antimicrobial peptide (AMP) isolated from the venom of the scorpion *Vaejovis mexicanus* with antimicrobial, anticancer and antimalarial activities, which the rational design with Arg-substitution has yielded AMPs with higher antimicrobial activity than VmCT1. Chagas is a neglected tropical disease, becoming the development of new antichagasic agents is urgent. Thus, we aimed to evaluate the antichagasic effect of VmCT1 and three Arg-substituted analogues, as well their action mechanism. Peptides were tested against the epimastigote, trypomastigote, amastigote forms of *Trypanosoma cruzi* Y strain and against LLC-MK2 mammalian cells. The mechanism of action of these peptides was evaluated by means of flow cytometry and scanning electron microscopy. VmCT1 presented activity against all three forms of *T. cruzi*, with EC<sub>50</sub> against trypomastigote forms of 1.37 μmol L<sup>-1</sup> and selectivity index (SI) of 58. [Arg]<sup>3</sup>-VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 also showed trypanocidal effect, but [Arg]<sup>11</sup>-VmCT1 had the best effect, being able to decrease the EC<sub>50</sub> against trypomastigote forms to 0.8 μmol L<sup>-1</sup> and increase SI to 175. Necrosis was cell death pathway of VmCT1, as well [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1, such as observed by membrane damage in flow cytometry analyses and scanning-electron-microscopy. In conclusion, [Arg]<sup>11</sup>-VmCT1 revealed promising as a candidate for new antichagasic therapeutics.

**Introduction**

Chagas disease is an anthrozoosis prevalent in Latin America, although cases have been reported in Europe, USA, Japan, New Zealand, Australia and Canada. This disease is caused by the protozoan *Trypanosoma cruzi* (Lidani *et al.*, 2019). According to the World Health Organization, it is estimated that 8 million people are infected by *T. cruzi* worldwide leading to more than 10 000 deaths per year (WHO/TDR, 2012). After the acute phase, the infected subjects can develop chronic disease characterized by cardiomyopathy and megaviscera (Pérez-Molina and Molina, 2018). The available treatment for Chagas disease is limited to nifurtimox and benznidazole, however they are only effective in the acute phase (Lacerda *et al.*, 2016). Therefore, there is a pressing need for new and efficient alternatives for the treatment of Chagas disease.

Antimicrobial peptides (AMPs) are promising candidates for the treatment of infectious diseases (Lacerda *et al.*, 2016; Giovati *et al.*, 2018). AMPs from animal venom have been described by antichagasic activity (Bandeira *et al.*, 2018; Mello *et al.*, 2017; Lima *et al.*, 2018; Freire *et al.*, 2020). VmCT1 is an AMP isolated from the venom of the scorpion *Vaejovis mexicanus*, which contains 13 amino acid residues and an amidated C-terminal extremity (Phe-Leu-Gly-Ala-Leu-Trp-Asn-Val-Ala-Lys-Ser-Val-Phe-NH<sub>2</sub>). It presents antimicrobial activity against Gram-positive and Gram-negative bacteria (Ramírez-Carretero *et al.*, 2012).

The designed Arg-substituted analogues of VmCT1 with a higher net positive charge (+3), than the wild-type (+2) showed higher antimicrobial activity against Gram-positive, Gram-negative bacteria and fungi (Pedron *et al.*, 2019). Here, we evaluated the antichagasic activity of the scorpion venom peptide VmCT1 and its Arg-substituted analogues against the epimastigote, trypomastigote and amastigote forms of *T. cruzi*, as well as, their mechanism of action.

**Methodology***Solid-phase peptide synthesis, purification and analysis*

The peptide synthesis has been previously detailed by Torres *et al.* (Torres *et al.*, 2017). Briefly, we performed solid-phase peptide synthesis on a peptide synthesizer (PS3-Sync Technologies),

fluoromethoxycarbonyl (Fmoc) strategy and the peptides were anchored to a Rink Amide resin with a substitution degree of  $0.52 \text{ mmol g}^{-1}$ . The dry protected peptidyl-resin was cleaved by exposure to TFA/anisole/water (95:2.5:2.5, v:v:v) for 2 h at room temperature. The crude peptides were precipitated with anhydrous diethyl ether, separated from the ether-soluble reaction components by filtration, extracted from the resin with 60% acetonitrile in water, and lyophilized, according to Pedron *et al.* (2017).

The crude peptides were purified by semi-preparative reverse-phase high-performance liquid chromatography on a Delta Prep 600 (Waters Associates) and the selected fractions containing the purified peptides were pooled and lyophilized. The peptides were characterized by liquid-chromatography electrospray-ionization mass spectrometry using a Model 6130 Infinity mass spectrometer coupled to a Model 1260 high-performance liquid chromatography system (Agilent), which conditions have been previously described in details by Torres *et al.* (2017).

### Parasites and LLC-MK2 cells culture

LLC-MK2 kidney cells (ATCC CCL-7), epimastigote and trypomastigote forms of *T. cruzi* Y strain were kindly donated by the Laboratório de Bioquímica de Parasitas (Instituto de Química, Universidade de São Paulo, São Paulo, Brazil). As previously described by Bandeira *et al.* (2018), LLC-MK2 were maintained at  $37^\circ\text{C}$  under 5%  $\text{CO}_2$  atmosphere in Dulbecco's Modified Eagle Medium (DMEM) (Vitrocell, São Paulo, Brazil) containing 10% of foetal bovine serum (FBS) and antibiotics (penicillin  $100 \text{ U mL}^{-1}$  and streptomycin  $130 \mu\text{g mL}^{-1}$ ) (Bandeira *et al.*, 2018). These cells were infected by trypomastigote forms of *T. cruzi* to obtain amastigote forms and to maintain trypomastigote forms. The infection cycle was maintained weekly at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  atmosphere in DMEM medium (Vitrocell, São Paulo, Brazil) supplemented with antibiotics (penicillin  $100 \text{ U mL}^{-1}$  and streptomycin  $130 \mu\text{g mL}^{-1}$ ) and a 2% FBS. Epimastigotes were maintained weekly in Liver Infusion Tryptose (LIT) medium 10% FBS at  $28^\circ\text{C}$  (Meira *et al.*, 2015).

### Peptides activity assay against *T. cruzi* trypomastigote forms

The trypomastigote forms of *T. cruzi* were obtained according to the methodology described by Bandeira *et al.* (2018). Briefly, the trypomastigote forms of *T. cruzi* obtained by infecting LLCMK2 cells with trypomastigote in T-25/75  $\text{cm}^2$  flasks were harvested (800 g for 7 min), plated in 96-well plates ( $1 \times 10^6$  parasites/well) with 2-fold dilutions of VmCT1, [Arg]<sup>3</sup>-VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 (concentration ranging from 25 to  $0.19 \mu\text{mol L}^{-1}$  of peptide), PBS as negative control and benznidazole as positive control (concentrations ranging from 1000 to  $15.6 \mu\text{mol L}^{-1}$ ; Roche®, Basilea, Switzerland) and incubated at  $37^\circ\text{C}$  under 5%  $\text{CO}_2$  atmosphere in DMEM medium (Vitrocell, São Paulo, Brazil) supplemented with antibiotics (penicillin  $100 \text{ U mL}^{-1}$  and streptomycin  $130 \mu\text{g mL}^{-1}$ ) and 10% FBS (Adade *et al.*, 2014). After 24 h of incubation, cell viability was measured by counting in a haemocytometer chamber. Parasites treated with sterile PBS were considered negative controls (100% viability) and all experiments were carried out in triplicate.

### Cytotoxicity to mammalian cells

Cell viability was measured using a standard 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay (Vanden Berghe *et al.*, 2013). Briefly, LLC-MK2 cells were plated in DMEM medium 10% FBS supplemented with

antibiotics (penicillin  $100 \text{ U mL}^{-1}$  and streptomycin  $130 \mu\text{g mL}^{-1}$ ), treated with the same range of concentrations in 2-fold dilutions described in the previous section for VmCT1, [Arg]<sup>3</sup>-VmCT1, [Arg]<sup>7</sup>-VmCT1 or [Arg]<sup>11</sup>-VmCT1, and benznidazole and incubated at  $37^\circ\text{C}$  for 24 h. The cells were incubated for 4 h in the presence of MTT (Amresco, Ohio, USA;  $5 \text{ mg mL}^{-1}$ ) after that a 10% sodium dodecyl sulphate (SDS; Vetec, São Paulo, Brazil) solution was added to solubilize the formazan product. Cell viability was assessed by absorbance at 570 nm on a microplate reader (Biochrom® Asys Expert Plus) (Bandeira *et al.*, 2018). Cells treated with sterile PBS were considered negative controls (100% viability). The  $\text{EC}_{50}$  was determined by non-linear regression and the selectivity index (SI) was calculated by the formula:  $\text{EC}_{50}$  of LLC-MK2/ $\text{EC}_{50}$  of trypomastigote forms (Nwaka and Hudson, 2006).

### Effect of VmCT1 and analogues on *T. cruzi* amastigote forms

The effects of peptides on the amastigote forms were assessed as described by Lima *et al.* (2016). Briefly, LLC-MK2 cells were seeded on 24-well plates containing coverslips (13 mm of diameter) and cultured in DMEM medium supplemented with 10% FBS and antibiotics (penicillin  $100 \text{ U mL}^{-1}$  and streptomycin  $130 \mu\text{g mL}^{-1}$ ), at  $37^\circ\text{C}$ , in a 5%  $\text{CO}_2$  atmosphere, for 24 h. Next, the medium was removed and cells were infected with trypomastigote forms (parasite-host cell ratio of 20:1) in DMEM medium containing 2% FBS. After 48 h of incubation, the infected cells were washed and treated with the half maximal effective concentration ( $\text{EC}_{50}$ ) of trypomastigotes of the peptides VmCT1, [Arg]<sup>7</sup>-VmCT1 or [Arg]<sup>11</sup>-VmCT1. The coverslips were collected after 24 h, washed with PBS, fixed in Bouin's solution and stained with Giemsa, according to Lima *et al.* (2016). Non-treated infected cells were used as negative control and benznidazole at  $282 \mu\text{mol L}^{-1}$  was used as positive control. Amastigote cells per 100 cells were determined by counting 300 cells from the different groups obtained from different wells.

### VmCT1 and analogues activity assay against *T. cruzi* epimastigote forms

Epimastigote forms of *T. cruzi* Y strain at exponential stage were harvested (800 g for 5 min), plated in 96-well plates ( $1 \times 10^6$  parasites/well) and exposed to VmCT1, [Arg]<sup>3</sup>-VmCT1, [Arg]<sup>7</sup>-VmCT1 or [Arg]<sup>11</sup>-VmCT1 at concentrations ranging from 100 to 0.78 (2-fold dilutions) in LIT medium supplemented with antibiotics (penicillin  $100 \text{ U mL}^{-1}$  and streptomycin  $130 \mu\text{g mL}^{-1}$ ) and 10% FBS. Benznidazole (2-fold dilutions with concentrations ranging from 1000 to  $15.6 \mu\text{mol L}^{-1}$ ) was used as positive control. Parasite growth inhibition was quantified in a haemocytometer chamber after incubation at  $28^\circ\text{C}$  for 24, 48 and 72 h (Rodrigues *et al.*, 2014). Parasites treated with sterile PBS medium were considered negative controls (100% viability) and all experiments were carried out in triplicate.

### *T. cruzi* epimastigote death pathway assays

Flow cytometry was performed to investigate the cell death pathway of epimastigote forms of *T. cruzi* (Mello *et al.*, 2017) at exponential stage, when exposed to VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1. Briefly, the parasites were treated with the  $\text{EC}_{50}$  values of each peptide in LIT medium and incubated for 24 h, washed and stained with different probes (according to the manufacturer's instructions) to evaluate cell death pathway. Phycoerythrin-conjugated annexin V (Annexin V-PE) and/or 7-AAD (7-aminoactinomycin D; BD Pharmingen, California, USA) were used to evaluate the externalization of

**Table 1.** Effect of VmCT1 and analogues against trypomastigote form of *Trypanosoma cruzi* Y strain and LLC-MK2 mammalian cells, and their respective selectivity index (SI)

	VmCT1	[Arg] <sup>3</sup> -VmCT1	[Arg] <sup>7</sup> -VmCT1	[Arg] <sup>11</sup> -VmCT1	BZ
Trypomastigote (EC <sub>50</sub> )	1.37 ± 0.13	0.67 ± 0.11	1.15 ± 0.11	0.8 ± 0.07	282 ± 20
LLC-MK2 (IC <sub>50</sub> )	79.68 ± 25	15.05 ± 1.04	66.47 ± 17.03	140 ± 68	614.8 ± 30
SI	58.16	22.3	57.8	175	2.18

EC<sub>50</sub> values are expressed in  $\mu\text{mol L}^{-1}$ . Data are expressed as means ± standard error of the mean (S.E.M.) of three independent experiments. BZ = benznidazole.

**Table 2.** Effect of VmCT1 and analogues against epimastigote forms of *Trypanosoma cruzi* Y strain

	VmCT1	[Arg] <sup>3</sup> -VmCT1	[Arg] <sup>7</sup> -VmCT1	[Arg] <sup>11</sup> -VmCT1	BZ
EC <sub>50</sub> /24 h	13.37 ± 3.1	9.18 ± 3.95	5.37 ± 0.65	42.82 ± 12.3	218 ± 15
EC <sub>50</sub> /48 h	20.41 ± 5.1	25.52 ± 7.68	6.02 ± 0.42	39.45 ± 4.4	61.1 ± 3
EC <sub>50</sub> /72 h	22.62 ± 3.0	27.59 ± 7.39	5.77 ± 0.63	74.46 ± 16.0	16.5 ± 1

EC<sub>50</sub> values are expressed in  $\mu\text{mol L}^{-1}$ . Data are expressed as means ± standard error of the mean (S.E.M.) of three independent experiments. BZ = benznidazole.

phosphatidylserine (Annexin V-PE) and/or membrane damage (7-AAD); 2',7'-Dichlorofluorescein diacetate (DCFH-DA; 20  $\text{mmol L}^{-1}$ ) was used to evaluate the reactive oxygen species (ROS) formation; and rhodamine 123 (10  $\mu\text{g mL}^{-1}$ ) was used to evaluate mitochondrial transmembrane potential. Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP; 39  $\mu\text{mol L}^{-1}$ ) was used as positive control in rhodamine 123 and DCFH-DA assays. Next, the samples were screened in a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA), in which 10 000 live events were collected and analysed using the CellQuest software (Becton-Dickinson, San Jose, CA). Epimastigotes treated with PBS were used as negative controls and experiments were carried out in triplicate.

### Scanning electron microscopy (S.E.M.)

The epimastigote forms were treated with the EC<sub>50</sub> values of VmCT1, [Arg]<sup>7</sup>-VmCT1 or [Arg]<sup>11</sup>-VmCT1 and incubated for 12 h. After incubation, the parasites were fixed for 2 h with 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, Pennsylvania), washed, dehydrated, dried with CO<sub>2</sub>, coated in gold and observed in a FEG Quanta 450 scanning electron microscope (FEI, Oregon, USA), according to Lima *et al.* (2018).

### Statistical analysis

The statistical analysis was performed on GraphPad Prism 6 program (GraphPad Software, San Diego, CA, USA). The half maximal effective concentration (EC<sub>50</sub>) values were calculated by non-linear regression. Data were analysed using one-way analysis of variance followed by Bonferroni's post-test. Significance was defined as \* $P < 0.05$ .

### Results

The natural AMP VmCT1 and its three Arg-substituted analogues were evaluated against the three developmental forms of *T. cruzi*. The wild-type peptide presented EC<sub>50</sub> at 1.37 ± 0.13  $\mu\text{mol L}^{-1}$  against trypomastigote forms and SI higher than 50 (58.16). The analogues [Arg]<sup>3</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 showed EC<sub>50</sub> against trypomastigote forms at lower concentrations values compared to VmCT1 (Table 1). These analogues presented different toxicity profiles towards LLC-MK2 mammalian cells, [Arg]<sup>3</sup>-VmCT1 presented higher activity against LLC-MK2


mammalian cells, decreasing the SI to 22. [Arg]<sup>11</sup>-VmCT1 presented the best selectivity among all the peptides tested (175) (Table 1), whereas [Arg]<sup>7</sup>-VmCT1 presented similar activity and selectivity to VmCT1.

Against the epimastigote form of the parasite, [Arg]<sup>3</sup>-VmCT1 did not show significant difference on EC<sub>50</sub> values compared to VmCT1 at any of the three incubation periods analysed. The analogue [Arg]<sup>7</sup>-VmCT1 showed the highest activity against epimastigotes compared to the wild-type and the other analogues, especially after 24 h of incubation with the parasites. Although [Arg]<sup>11</sup>-VmCT1 was the most effective on trypomastigote forms, it was the less active on epimastigote forms (Table 2).

Due to the SI lower than 50 (22), [Arg]<sup>3</sup>-VmCT1 was not used in further studies. Thus, VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 were tested against amastigote forms of *T. cruzi*. The three peptides were able to decrease the number of amastigotes per 100 cells after 24 h of incubation (Fig. 1). The mechanism of action of the peptides was assessed by flow cytometry and confirmed by scanning electron microscopy (S.E.M.). The membrane damage caused by the peptides was monitored with 7AAD (indicating plasma membrane lesion necrosis) and Annexin-V (apoptosis marker by the externalization of phosphatidylserine) staining, ROS formation was followed by labelling with DCFH-DA and mitochondrial transmembrane potential was assessed by labelling with rhodamine 123.

After 24 h of incubation, the EC<sub>50</sub> of VmCT1 increased the 7AAD + /AX- population from 0.2 to 9.2% (Fig. 2a), led to higher formation of ROS (33%) (Fig. 3a) and reduced 56% of the mitochondrial transmembrane potential (Fig. 4a). At the EC<sub>50</sub> concentration value of [Arg]<sup>7</sup>-VmCT1, we observed the increase of the 7AAD + /AX- population to 7% (Fig. 2b), with no significant alterations on the formation of ROS (Fig. 3b) or mitochondrial transmembrane potential (Fig. 4b). The analogue [Arg]<sup>11</sup>-VmCT1, at EC<sub>50</sub> concentration, caused an increase in the 7AAD + /AX- population to 45% (Fig. 2c), a reduction of 60% of mitochondrial transmembrane potential (Fig. 4c) and no significant alterations on the formation of ROS (Fig. 3c). FCCP, an uncoupler, used as positive control was able to increase ROS formation in three times (Fig. 3) and to reduce mitochondrial transmembrane potential about 60% (Fig. 4).

These results were confirmed by S.E.M. images, which showed pore formation on the parasite membrane in the treatment with



**Fig. 1.** The effect of EC<sub>50</sub> from trypomastigote forms of VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 on intracellular amastigote forms of *Trypanosoma cruzi*. (CT: negative control - PBS).

the three peptides (Fig. 5), indicating that these peptides damaged the membrane of the parasite.

## Discussion

Natural AMPs from animal venoms have been reported as anti-protozoal agents (Vinhote *et al.*, 2017; Bandeira *et al.*, 2018; Lima *et al.*, 2018). They also are promising molecular scaffolds for drug engineering, aiming antimicrobial agents with low toxicity and higher biological activity (Ortiz *et al.*, 2015; Fratini *et al.*, 2017). These molecules are abundant in scorpion venoms, such as VmCT1 in *V. mexicanus smihi* scorpion venom. Previously, we designed VmCT1 analogues exploring different physicochemical and structural properties which led to increased

antimicrobial activity and lower cytotoxicity (Pedron *et al.*, 2017; 2019). Due to the biotechnological potential of VmCT1 and VmCT1-derived peptides, we analysed their antichagasic effects. We evaluated these peptides against the *T. cruzi* main forms (epimastigotes, trypomastigotes, amastigotes) and their cell death pathway.

A previous work with stigmurin, AMP isolated from venom of the scorpion *Tityus stigmurus* with trypanocidal effect and low hemolytic activity, performed a rational design obtaining the peptides StigA6, StigA16 with higher net charge and hydrophobic moment, being able to inhibit the parasites with lower concentrations, when compared to native stigmurin (Amorim-Carmo *et al.*, 2019). In this work, against trypomastigotes, native VmCT1 presented an EC<sub>50</sub> of  $1.37 \pm 0.13 \mu\text{mol L}^{-1}$  and the EC<sub>50</sub> of the analogues decreased ( $0.67\text{--}1.15 \mu\text{mol L}^{-1}$ ). Although the low decrease on EC<sub>50</sub> of trypomastigotes, the SI of one of the analogues increased in three times, from 58 to 175.


Modifications on physicochemical parameters such as net positive charge, mean hydrophobicity and mean hydrophobic moment can influence on biological activities (Pedron *et al.*, 2017; 2019; Torres *et al.*, 2017; 2018). [Arg]<sup>3</sup>-VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 presented mean hydrophobicity values of 0.65, 0.71 and 0.66, respectively – estimated by the heliQuest server (Gautier *et al.*, 2008); which are lower than the wild-type's mean hydrophobicity (0.82) and reported as the reason that led these peptides to higher antimicrobial activity towards microorganisms (Pedron *et al.*, 2019). Here, we observed similar effect when the peptides were tested against *T. cruzi*.

According to the WHO/TDR, one criteria for considering a molecule as a potential antitrypanosomal agent is presenting a SI higher than 50 (Nwaka and Hudson, 2006). VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 presented SI values higher than the criteria limit, and among all the peptides, [Arg]<sup>11</sup>-VmCT1 is the most promising antichagasic molecule, with the highest SI (175) and EC<sub>50</sub> values against trypomastigote forms lower than  $1 \mu\text{mol L}^{-1}$ .


The selectivity of the AMPs to pathogens is related to their cationicity. It is an important physicochemical feature that influences peptide-membrane interactions (de la Fuente-Nunez *et al.*, 2017; Torres *et al.*, 2019), once it is related to the initial electrostatic interactions between AMPs and the negatively charged phospholipids present in the membranes of microorganisms (Lohner, 2017; Stutz *et al.*, 2017). Arg residues present a side chain guanidinium group with delocalized positive charge density (Armstrong *et al.*, 2016), which its replacement in strategical sites could increase the SI.

The replacement of serine by arginine at position 11 led the guanidyl side chain group of this amino acid to interact with water molecules and lipids groups of phospholipids, promoting the formation of hydrogen bonds that can lead to destabilization and disruption or permeabilization of membranes. Furthermore, in previous analyses by circular dichroism spectroscopy, when the peptides were exposed to negatively charged lipid vesicles of POPC:POPG (palmitoyl oleoyl phosphatidylcholine: palmitoyl oleoyl phosphatidylglycerol, 3:1, mol:mol,  $10 \text{ mmol L}^{-1}$ ), [Arg]<sup>11</sup>-VmCT1 analogue presented lower helical content than the other analogues, which also could be related to the best effect (Pedron *et al.*, 2019).

Beyond selectivity, the effect on intracellular forms has also fundamental importance, because they are the forms that maintain the infection during the chronic phase, phase in which the current treatment is only 20% effective (Urbina and Docampo, 2003; Morilla and Romero, 2015). In this work, VmCT1, [Arg]<sup>7</sup>-VmCT1 and [Arg]<sup>11</sup>-VmCT1 were able to decrease the number of amastigote/100 cells after 24 h of incubation at



**Fig. 2.** Flow cytometry of *Trypanosoma cruzi* epimastigote forms treated with (a) VmCT1 at  $13.4 \mu\text{mol L}^{-1}$ , (b)  $[\text{Arg}]^7\text{-VmCT1}$  at  $5.4 \mu\text{mol L}^{-1}$  and (c)  $[\text{Arg}]^{11}\text{-VmCT1}$  at  $42.8 \mu\text{mol L}^{-1}$  for 24 h. Percentages values are averages of 10 000 live events from three independent experiments (CT: negative control - PBS).



**Fig. 3.** Flow cytometry analysis of the formation of ROS in *Trypanosoma cruzi* epimastigotes exposed to peptides. 2',7'-dichlorofluorescein (DCF) fluorescent signal and relative fluorescence values from experiments with *T. cruzi* epimastigotes in exponential stage that were treated for 24 h with (a) VmCT1 at  $13.4 \mu\text{mol L}^{-1}$ , (b)  $[\text{Arg}]^7\text{-VmCT1}$  at  $5.4 \mu\text{mol L}^{-1}$  and (c)  $[\text{Arg}]^{11}\text{-VmCT1}$  at  $42.8 \mu\text{mol L}^{-1}$ . The measurements were obtained from three independent experiments. (CT: negative control - PBS).

concentrations lower than  $1.5 \mu\text{mol L}^{-1}$ , being lower than  $1 \mu\text{mol L}^{-1}$  on  $[\text{Arg}]^{11}\text{-VmCT1}$ .


AMPs from arthropods have been showed different action mechanisms (Sabiá Júnior *et al.*, 2019), such as mastoparan from *Polybia paulista* wasp venom, which inhibits glyceraldehyde-3-phosphate dehydrogenase from *T. cruzi* (TcGAPDH), a key enzyme in the glycolytic pathway (Vinhote *et al.*, 2017), while *Polybia-CP*, another AMP from the same venom did not show the same enzymatic inhibition, but showed apoptotic effect (Freire *et al.*, 2020). Otherwise, M-PONTX-Dq3a from *Dinoponera quadricaps* ant venom showed necrotic mechanism on *T. cruzi*. (Lima *et al.*, 2018). In this work, epimastigotes treated with the peptides (VmCT1,  $[\text{Arg}]^7\text{-VmCT1}$  and  $[\text{Arg}]^{11}\text{-VmCT1}$ ) presented higher effect at lower times of incubation, suggesting a fast action mechanism, such as necrosis. They also showed an increase in membrane permeation on flow cytometry analyses.

Flow cytometry also were used to evaluate the intracellular formation of ROS and transmembrane mitochondrial potential

(Bandeira *et al.*, 2018). VmCT1 was the only peptide tested that led to an increase on the formation of ROS. The transmembrane mitochondrial potential was decreased by the peptides VmCT1 and  $[\text{Arg}]^{11}\text{-VmCT1}$  compared to the negative control. In addition, S.E.M. images showed damage on the membrane of parasites treated with all peptides, showing presence of pore.

The plasma membrane disruption is well established as the most characteristic necrotic event (Menna-Barreto, 2019), meaning all peptides act through necrosis. VmCT1,  $[\text{Arg}]^7\text{-VmCT1}$  and  $[\text{Arg}]^{11}\text{-VmCT1}$  showed the same action mechanism, implying the Arg-substitution in the positions 7 and 11 were not able to change the cell death pathway.

Some AMPs from animal venoms with necrotic mechanism on *T. cruzi*, such as crotalicidin (Bandeira *et al.*, 2018), batroxicidin (Mello *et al.*, 2017) and M-PONTX-Dq3a (Lima *et al.*, 2018) are in agreement with the criteria of  $\text{SI} > 50$  from WHO guidelines for prospection of new drugs (Nwaka and Hudson, 2006), as well the peptide family from this work, while benznidazole showed  $\text{SI} < 3$  in the same strain.




**Fig. 4.** Flow cytometry analysis of mitochondrial transmembrane potential changes in *Trypanosoma cruzi* epimastigotes exposed to peptides. Rhodamine 123 (Rho 123) fluorescent signal and relative fluorescence values from experiments with *T. cruzi* epimastigotes in exponential stage that were treated for 24 h with (a) VmCT1 at  $13.4 \mu\text{mol L}^{-1}$ , (b)  $[\text{Arg}]^7\text{-VmCT1}$  at  $5.4 \mu\text{mol L}^{-1}$  and (c)  $[\text{Arg}]^{11}\text{-VmCT1}$  at  $42.8 \mu\text{mol L}^{-1}$ . The measurements were obtained from three independent experiments. (CT: negative control - PBS).

Besides the SI, the haemolytic effect of this peptide family was previously described and we demonstrated a maximal non-haemolytic concentration of 6.3, 1.6, 3.1 and  $3.1 \mu\text{mol L}^{-1}$  for VmCT1,  $[\text{Arg}]^3\text{-VmCT1}$ ,  $[\text{Arg}]^7\text{-VmCT1}$  e  $[\text{Arg}]^{11}\text{-VmCT1}$ , respectively (Pedron *et al.*, 2019).  $[\text{Arg}]^{11}\text{-VmCT1}$ , peptide with the best effect, showed no haemolytic effect in concentrations almost four times bigger than  $\text{EC}_{50}$  of trypomastigote forms, which is the same concentration able to reduce number of amastigotes per 100 cells.

Benznidazole has been used against chronic Chagas disease for almost 50 years, but treatment failures (6–50%) are reported in recent clinical trials. Other problematic factors include the extended treatment length (often 60–90 days) and

frequent toxic side-effects (Campos *et al.*, 2017). It also has low penetrability in membrane, being necessary high gradients of concentrations to gain amastigote forms (Morilla and Romero, 2015). The toxicity, low selectivity and the necessity of high gradients of concentrations of benznidazole contribute with the treatment failures. In this work, we described one peptide able to reduce 50% of trypomastigote (blood circulating) form viability in concentrations lower than  $1 \mu\text{mol L}^{-1}$ . In this same concentration also was able to reduce about 50% the number of amastigote per 100 cells in a short time of incubation, such as 24 h. Although this work showed only *in vitro* tests, these characteristics are desirable to therapeutic alternatives to benznidazole.



**Fig. 5.** Scanning electron microscopy of *Trypanosoma cruzi* epimastigotes treated with peptides. (a) Control epimastigotes treated with PBS, (b) treated with  $EC_{50}$  of VmCT1, (c)  $[Arg]^7$ -VmCT1 and (d)  $[Arg]^{11}$ -VmCT1. Scale bar:  $5\ \mu m$ .

## Conclusion

The scorpion venom peptide VmCT1 presented antichagasic activity against the principal developmental forms of *T. cruzi*, which was improved in potency and selectivity with an Arg-substitution in position 11, maintaining the mechanism of action of VmCT1, which was necrotic. These results revealed that  $[Arg]^{11}$ -VmCT1 is a promising candidate for the development of new therapeutics against Chagas disease.

**Acknowledgments.** The authors are thankful to the Analytical Center Core Facility of the Federal University of Ceará for the technical support on Electron Microscopy studies and the Multiuser Central Facilities (UFABC) for the experimental support.

**Financial support.** The authors thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) for funding (PNPD 88887.368537/2019-00 and Finance Code 001) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) for funding (VXO #2017/03046-2).

**Conflict of interest.** The authors declare that they do not have conflict of interest.

**Ethical standards.** Not applicable.

## References

Adade CM, Carvalho ALOLO, Tomaz MA, Costa TFR, Godinho JL, Melo PA, Lima APCA, Rodrigues JCF, Zingali RB, Souto-Padrón T and Souto-Padrón T (2014) Crovirin, a snake venom cysteine-rich secretory

protein (CRISP) with promising activity against trypanosomes and leishmania. *PLoS Neglected Tropical Diseases* **8**, e3252.

Amorim-Carmo B, Daniele-Silva A, Parente AMS, Furtado AA, Carvalho E, Oliveira JWF, Santos ECG, Silva MS, Silva SRB, Silva-Júnior AA, Monteiro NK and Fernandes-Pedrosa MF (2019) Potent and broad-spectrum antimicrobial activity of analogs from the scorpion peptide stigmurin. *International Journal of Molecular Sciences* **20**, 623.

Armstrong CT, Mason PE, Anderson JLR and Dempsey CE (2016) Arginine side chain interactions and the role of arginine as a gating charge carrier in voltage sensitive ion channels. *Scientific Reports* **6**, 1–10.

Bandeira ICJ, Bandeira-Lima D, Mello CP, Pereira TP, De Menezes RRPPB, Sampaio TL, Falcão CB, Rádis-Baptista G and Martins AMC (2018) Antichagasic effect of crotalicidin, a cathelicidin-like viperidicin, found in *Crotalus durissus terrificus* rattlesnake's venom gland. *Parasitology* **145**, 1059–1064.

Campos MC, Phelan J, Francisco AF, Taylor MC, Lewis MD, Pain A, Clark TG and Kelly JM (2017) Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. *Scientific Reports* **7**, 14407.

de la Fuente-Nunez C, Torres MD, Mojica FJ and Lu TK (2017) *Next-generation Precision Antimicrobials: Towards Personalized Treatment of Infectious Diseases*. UK: Elsevier Ltd. doi: 10.1016/j.mib.2017.05.014.

Fratini F, Cilia G, Turchi B and Felicoli A (2017) Insects, arachnids and centipedes venom: a powerful weapon against bacteria. A literature review. *Toxicon* **130**, 91–103.

Freire KA, Torres MDT, Lima DB, Monteiro ML, de Menezes RRPPB, Martins AMC and Oliveira VX (2020) Wasp venom peptide as a new antichagasic agent. *Toxicon* **181**, 71–78.

Gautier R, Douguet D, Antony B and Drin G (2008) HELIQUEST: a web server to screen sequences with specific  $\alpha$ -helical properties. *Bioinformatics (Oxford, England)* **24**, 2101–2102.



- Giovati L, Ciociola T, Magliani W and Conti S (2018) Antimicrobial peptides with antiprotozoal activity: current state and future perspectives. *Future Medicinal Chemistry* **10**, 2569–2572.
- Lacerda AF, Pelegrini PB, De Oliveira DM, Vasconcelos ÉAR and Grossi-de-Sá MF (2016) Anti-parasitic peptides from arthropods and their application in drug therapy. *Frontiers in Microbiology* **7**, 1–11.
- Lidani KCF, Andrade FA, Bavia L, Damasceno FS, Beltrame MH, Messias-Reason IJ and Sandri TL (2019) Chagas disease: from discovery to a worldwide health problem. *Journal of Physical Oceanography* **49**, 166. doi: 10.3389/fpubh.2019.00166
- Lima DBDB, Sousa PL, Torres AFCAFC, Rodrigues KADFKAdA, Mello CPCP, Menezes RRPPBDRRPPBdeRRPPBD, Tessarolo LDLDL, Quinet YPYYP, de Oliveira MR and Martins AMCAMC (2016) Antiparasitic effect of *Dinoponera quadriceps* giant ant venom. *Toxicon* **120**, 128–132.
- Lima DB, Mello CP, Bandeira ICJ, De Menezes RRPPB, Sampaio TL, Falcão CB, Morlighem J-ÉÉRL, Rádis-Baptista G and Martins AMC (2018) The dinoponeratoxin peptides from the giant ant *Dinoponera quadriceps* display in vitro antitrypanosomal activity. *Biological Chemistry* **399**, 187–196.
- Lohner K (2017) Membrane-active antimicrobial peptides as template structures for novel antibiotic agents. *Current Topics in Medicinal Chemistry* **17**, 508–519.
- Meira CS, Guimarães ET, Dos Santos JAF, Moreira DRM, Nogueira RC, Tomassini TCB, Ribeiro IM, de Souza CVC, Ribeiro Dos Santos R and Soares MBP (2015) In vitro and in vivo antiparasitic activity of *Physalis angulata* L. concentrated ethanolic extract against trypanosoma cruzi. *Phytomedicine: international journal of phytotherapy and phytopharmacology* **22**, 969–974.
- Mello CPCP, Lima DBDB, Menezes RRPPBdeRRPPBD, Bandeira ICJICJ, Tessarolo LDLD, Sampaio TLTL, Falcão CBCB, Rádis-Baptista G and Martins AMCAMC (2017) Evaluation of the antichagasic activity of batroxidicin, a cathelicidin-related antimicrobial peptide found in bothrops atrox venom gland. *Toxicon* **130**, 56–62.
- Menna-Barreto RFS (2019) Cell death pathways in pathogenic trypanosomatids: lessons of (over)kill. *Cell Death and Disease* **10**. doi: 10.1038/s41419-019-1370-2.
- Morilla MJ and Romero EL (2015) Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. *Nanomedicine: Nanotechnology, Biology, and Medicine* **10**, 465–481.
- Nwaka S and Hudson A (2006) Innovative lead discovery strategies for tropical diseases. *Nature Reviews Drug Discovery* **5**, 941–955.
- Ortiz E, Gurrola GB, Schwartz EF and Possani LD (2015) Scorpion venom components as potential candidates for drug development. *Toxicon* **93**, 125–135.
- Pedron CN, Torres MDT, Lima JAdA, Silva PI, Silva FD and Oliveira VX (2017) Novel designed VmCT1 analogs with increased antimicrobial activity. *European Journal of Medicinal Chemistry* **126**, 456–463.
- Pedron CN, Araújo I, da Silva Junior PI, da Silva D, Torres F, T MD and Oliveira Junior VX (2019) Repurposing the scorpion venom peptide VmCT1 into an active peptide against gram-negative ESKAPE pathogens. *Bioorganic Chemistry* **90**, 103038.
- Pérez-Molina JA and Molina I (2018) Chagas disease. *The Lancet* **391**, 82–94.
- Ramírez-Carreto S, Quintero-Hernández V, Jiménez-Vargas JM, Corzo G, Possani LD, Becerril B and Ortiz E (2012) Gene cloning and functional characterization of four novel antimicrobial-like peptides from scorpions of the family Vaejovidae. *Peptides* **34**, 290–295.
- Rodrigues JHdaS, Ueda-Nakamura T, Corrêa AG, Sangi DP and Nakamura CV (2014) A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with Benznidazole, against *Trypanosoma cruzi*. *PLoS ONE* **9**, e85706.
- Sabiá Júnior EF, Menezes LFS, de Araújo IFS and Schwartz EF (2019) Natural occurrence in venomous arthropods of antimicrobial peptides active against protozoan parasites. *Toxins* **11**, 563.
- Stutz K, Müller AT, Hiss JA, Schneider P, Blatter M, Pfeiffer B, Posselt G, Kanfer G, Kornmann B, Wrede P, Altmann K-H, Wessler S and Schneider G (2017) Peptide-membrane interaction between targeting and Lysis. *ACS Chemical Biology* **12**, 2254–2259.
- Torres MDT, Pedron CN, Araújo I, Silva PI, Silva FD and Oliveira VX (2017) Decoralin analogs with increased resistance to degradation and lower hemolytic activity. *ChemistrySelect* **2**, 18–23.
- Torres MDT, Pedron CN, Higashikuni Y, Kramer RM, Cardoso MH, Oshiro KGN, Franco OL, Silva Junior PI, Silva FD, Oliveira Junior VX, Lu TK and de la Fuente-Nunez C (2018) Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates. *Communications Biology* **1**, 1–16.
- Torres MDT, Sothiselvam S, Lu TK and de la Fuente-Nunez C (2019) Peptide design principles for antimicrobial applications. *Journal of Molecular Biology* **431**, 3547–3567.
- Urbina JA and Docampo R (2003) Specific chemotherapy of chagas disease: controversies and advances. *Trends in parasitology* **19**, 495–501.
- Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N and Vandenabeele P (2013) Determination of apoptotic and necrotic cell death in vitro and in vivo. *Methods (San Diego, Calif.)* **61**, 117–129.
- Vinhote JFCJFC, Lima DBDB, Menezes RRPPBDRRPPBde, Mello CPCP, de Souza BMBM, Havt A, Palma MSMS, Santos RPDRPdOs, Albuquerque ELdeELD, Freire VNVN and Martins AMCAMC (2017) Trypanocidal activity of mastoparan from *Polybia paulista* wasp venom by interaction with TcGAPDH. *Toxicon* **137**, 168–172.
- WHO/TDR (2012). Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis: WHO Technical Report Series (No. 975). Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis Research Priorities for Chagas Disease. doi: ISSN 0512-3054.